PSA/IL-2/GM-CSF vaccine - Oncbiomune

Drug Profile

PSA/IL-2/GM-CSF vaccine - Oncbiomune

Alternative Names: ProscaVax; Prostatac; Prostate cancer vaccine - Oncbiomune

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Oncbiomune
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 26 Jan 2017 Updated efficacy data from a phase I trial in Prostate cancer released by OncBioMune
  • 12 Dec 2016 OncBioMune receives patent allowance for PSA/IL-2/GM-CSF cancer vaccine in Europe
  • 19 Oct 2016 OncBioMune receives patent allowance for PSA/IL-2/GM-CSF in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top